受者同系骨髓间充质干细胞对大鼠心脏移植排斥反应的影响
|
摘要
第一部分大鼠颈部心脏移植模型的建立
目的:建立成功率较高的大鼠颈部异位心脏移植模型。
方法:采用自制的套管连接血管建立移植心脏血流通路:移植心脏无名动脉连接大鼠右颈总动脉,移植心脏左肺动脉连接大鼠右颈外静脉,建立大鼠颈部心脏移植模型。术后24小时移植心脏正常跳动视为移植成功。
结果:建模成功率为88%(30/34)。
结论:成功应用套管法建立了大鼠颈部心脏移植模型。
第二部分大鼠骨髓间充质干细胞的体外分离、培养与鉴定
目的:建立稳定的大鼠骨髓间充质干细胞(Mesenchymal stem cells,MSC)体外分离、培养、鉴定方法。
方法:选用1月龄雄性清洁级Wistar大鼠,处死消毒后取其胫骨和股骨,用含15%胎牛血清DMEM冲洗骨髓腔,收集冲洗液,采用密度梯度离心法分离获取细胞,培养后对贴壁细胞进行传代培养。取第3代生长状态良好的细胞,以流式细胞术鉴定细胞表型,并进行冻存复苏实验。
结果:MSC在培养瓶中24h后就有细胞贴壁,第3～4d细胞生长明显,经换液去除未贴壁细胞,传代后细胞生长迅速,约6～8d即可长满培养瓶底,达融合状态,三代后即可得到较为纯化的MSC成纤维样细胞,并至少可传代10代以上,冻存对细胞生长无影响。流式细胞术检测细胞表面分子标志,显示CD11B(-)、CD29(+)、CD34(-)、CD45(-)、CD90(+)、CD106(+)。
结论:通过密度梯度离心及贴壁筛选培养法获取大鼠骨髓MSC的方法简便易行,可提供稳定的大鼠MSC。
第三部分受者同系骨髓间充质干细胞对大鼠心脏移植急性排斥反应的影响
目的:观察受者同系骨髓MSC对大鼠心脏移植急性排斥反应的影响,并探讨MSC的免疫调节机制。
方法:实验动物随机分为2组,每组10只受体,进行Lewis→Wistar颈部心脏移植:(1)空白对照组(A_3组):手术后24h,确定手术成功,即经尾静脉注射3mL0.9%氯化钠注射液;(2)MSC处理组(B_3组):手术后24h,确定手术成功,即经尾静脉注射MSC2×10~6(悬浮在3mL0.9%氯化钠注射液中)。术后一周,每组随机取4只大鼠,取下腔静脉血及移植物进行组织学及免疫学检查。检测项目:病理学分级,血清IL-2及IL-10,血、移植物CD4~+、CD8~+、CD4~+CD25~(high)、CD4~+CD25~(high)foxp3~+T细胞占总淋巴细胞的比例,及CD4~+/CD8~+比值。其余6只用以继续观察移植物存活时间。另外再建立2只大鼠心脏移植模型,术后24小时,经尾静脉注射表达绿色荧光蛋白的同系MSC(MSC~(GFfP))2×10~6,术后7天取移植心脏,冰冻切片,荧光显微镜下观察移植物内荧光细胞的分布情况。
结果:(1)A_3组大鼠移植心脏存活7.2±1.3d,B_3组大鼠移植心脏存活14.8±2.9d。P＜0.01。(2)血清IL-2:A_3组为233.99±30.19pg/mL,B_3组为249.11±20.34 pg/mL,P＞0.1;血清IL-10:A_3组为81.44±11.01 pg/mL,B_3组为158.39±18.70 pg/mL,P＜0.01。(3)病理学分级,A_3组3B级1例,4级3例;B_3组2级1例,3A级2例,3B级1例,B_3组病理分级总体较A_3组低。(4)大鼠血中CD4~+/CD8~+值、CD4~+CD25~(high)T细胞占总淋巴细胞的比例、CD4~+CD25~(high)Foxp3~+T细胞占总淋巴细胞的比例,B_3组都明显高于A_3组,差异有统计学意义(P＜0.01)。(5)移植心脏中CD4~+/CD8~+值两组之间无显著性差异,CD4~+CD25~(high)T细胞占总淋巴细胞的比例、CD4~+CD25~(high)Foxp3~+T细胞占总淋巴细胞的比例,B_3组都明显高于A_3组,差异有统计学意义(P＜0.01)。(6)心脏移植术后24h,经尾静脉向受体大鼠注射同系MSC~(GFP)后6天,荧光显微镜下观察移植心脏冰冻切片可见荧光细胞在移植心脏表面分布较集中,并向心肌组织浸润,形态及分布类似心肌细胞。
结论:静脉注射受者同系骨髓MSC,可以延长大鼠颈部移植心脏的存活时间,减轻急性排斥反应的程度。
第四部分受者同系骨髓间充质干细胞对大鼠心脏移植慢性排斥反应的影响
目的:观察受者同系骨髓MSC对大鼠心脏移植慢性排斥反应的影响。
方法:实验共设4组,每组5只受体大鼠,行颈部心脏移植手术:(1)同系移植组(A_4组):Wistar→Wistar,CsA2mg/kg·d腹腔注射14天;(2)慢性排斥组(B_4组):Lewis→Wistar,CsA 2mg/kg·d腹腔注射14天;(3)MSC处理组(C_4组):Lewis→Wistar,CsA 2mg/kg·d腹腔注射14天,术后第15天、第30天分别经尾静脉注射MSC2×10~6;(4)单纯CsA组(D_4组):Lewis→Wistar,CsA 2mg/kg·d腹腔注射至观察终点。观察终点为术后120天。届时,取移植心做病理检查,MASSON染色,分析心脏动脉管壁增厚情况及心肌间质胶原增生情况。
结果:所有受体及移植物均良好存活至观察终点。移植心脏内动脉管壁增厚比例(%):A_4组19.68±2.06,B_4组29.14±1.98,C_4组29.88±2.28,D_4组39.82±1.84。B_4-C_4组之间差异无统计学意义(P＞0.05)。胶原增生比例(%):A_4组8.76±1.56,B_4组17.98±2.40,C_4组19.50±2.24,D_4组17.64±2.47。A_4组纤维增生较其它各组明显减轻,差异有统计学意义(P＜0.01);B_4、C_4、D_4各组之间差异无统计学意义(P＞0.05)。
结论:早期应用CsA2周后,静脉输注受者同系MSC未能减轻移植心脏慢性排斥反应的程度。
PartⅠ
Establishment of a Cervical Heterotopic Cardiac Transplantation Model of Rats
Objectives:To establish a modified model of rat cervical heterotopic cardiac transplantation for high achievement ratio.
Methods:A right cervical heterotopic cardiac transplantation model of rats was established.The allograft blood circulation was established with cuff technique using home-made cannulas.Through the cannulas,the donor innominate artery was anastomosed to the recipient's right common carotid artery and donor left pulmonary artery to the recipient's external jugular vein.The successful standard of transplantation was the transplanted heart could beat rhythmically over 24 hours.
Results:Successful rate of heterotopic cardic transplantation is 88%(30/34).
Conclusions:A modified model of rat cervical heterotopic cardiac transplantation was established with cuff technique.
PartⅡ
Isolation,Culturing and Identification of Rat MSC From Bone Marrow in vitro
Objectives:To establish the methods for the isolation,culturing and identification of rat MSC from bone marrow in vitro.
Methods:One month old male Wistar rats were killed to get the tibias and femurs.After the long bones were dissected from rats,the marrows were flushed out with DMEM medium(supplemented with 15%fetal bovine serum) under aseptic condition and purified by Percoll gradient centrifugation to get the mononuclear cells.After the mononuclear cells were cultured,the adherent cells were chosen for serial subcultivation.The third generation cells were harvested and the cell phenotypes were identified by flow cytometry.
Results:The mesenchymal stem cells were adhered to plastic surface within 24h.The cell growth was obvious on the 3～4 days.Nonadherent cells were removed by changing the culture medium.After passage,the cells gown rapidly to fill the floor of cell culture flasks and achieved confluence within 6～8 days. Purified MSC fibroblast-like cells could be harvested after 3 generations.There was no obvious influence to cell growth when reserved in frozen condition.The cells could passage for at least 10 generations.The cell phenotypes identified by flow cytometry showed CD29(+)、CD34(-)、CD45(-)、CD11B(-)、CD90 (+)、CD106(+).
Conclusions:The methods of obtaining rat MSC with density gradient centrifugation and adherence cultivation was convenient,and could provide immortalized rat MSC lines.
PartⅢEffects of Bone Marrow Mesenchymal Stem Cells Derived from Recipients on the Acute Rejection in Rat Cardiac Transplantation Models
Objectives:To investigate the effects of MSC derived from recipients' bone marrow on the acute rejection of rat cardiac transplantation and study the possible underlying mechanisms.
Methods:Twenty Wistar rats beating transplanted heart from Lewis rats were divided randomly into 2 groups(10 rats each group ):(1)Control group (group A3):3mL 0.9%NaCl solution was injected through tail vein at 24h after heart transplantation.(2) Treatment group(group B_3):2×10~6 MSC in 3mL 0.9%NaCl solution was injected through tail vein at 24h after heart transplantation. One week after transplantation,4 rats randomly from each group were anaesthetized to get blood from inferior canal vein and allografts.Grafts pathology was studied.Serum levels of IL-2 and IL-10 was detected by method of ELISA.Flow cytometry was used to detect the ratio of CD4~+ T cells,CD8~+ T cells, CD4~+CD25~(high) T cells and CD4~+CD25~(high)foxp3~+ T cells in lymphocytes in the blood and grafts.The rest 6 rats in each group were observed survival time of grafts.Two other cardiac transplantation models were established.At 24h after transplantation,2×10~6 MSC~(GFP) were injected throug tail vein,respectively.The two grafts were harvested on 7~(th) day after transplantation to get frozen sections for observing the fluorescence cells in grafts.
Results:(1) The survival time of allografts:group A_3 was 7.2±1.3d,group B_3 was 14.8±2.9d.P＜0.01.(2)Concentrations of serum IL-2:group A_3 was 233.99±30.19pg/mL,group B_3 was 249.11±20.34 pg/mL,P＞0.1;IL-10:group A_3 was 81.44±11.01 pg/mL,group B_3 was 158.39±18.70 pg/mL,P＜0.01. (3)Pathology grade:group A_3:1 case was Grade 3B,3 cases were Grade 4;group B_3:1 case was Grade 2,2 cases were Grade 3A,1 case was Grade 3B.(4) Ratios of CD4~+/CD8~+,CD4~+CD25~(high) T cells/total lymphocytes and CD4~+CD25~(high)Foxp3~+ T cells/total lymphocytes in blood:group B3 was higher than group A_3,P＜0.01.(5) Ratios of CD4~+/CD8~+ in allografts were similar in two groups,P＞0.1;CD4~+CD25_(high)T cells/total lymphocytes and CD4~+CD25~(high)Foxp3~+ T cells/total lymphocytes in allografts:group B_3 was higher than group A_3, P＜0.01.(6) Fluorescence cells could be observed to concentrate to the surface of allografts,some cells had infiltrated into cardiac muscle and their shapes and distributions were just like cardiac muscle.
Conclusions:Intravenous infusion with MSC from recipients could prolong the survival time of transplanted heart and inhibit acute rejection.
PartⅣ
Effects of Bone Marrow Mesenchymal Stem Cells Derived from Recipients on the Chronic Rejection in Rat Cardiac Transplantation Models
Objectives:To observe the effects of mesenchymal stem cells derived from recipients' bone marrow on the chronic rejection of rat cardiac transplantation.
Methods:Twenty rats bearing transplanted hearts were divided randomly into 4 groups(5 rats each group):(1)Homologous transplantation group(group A_4):Wistar-Wistar,CsA 2mg/kg·d was injected into abdominal cavity for 14 days after transplantation;(2)Chronic rejection group(group B_4):Lewis-Wistar,CsA 2mg/kg·d was injected into abdominal cavity for 14 days after transplantation; (3)MSC treatment group(group C_4):Lewis-Wistar,CsA 2mg/kg·d was injected into abdominal cavity for 14 days after transplantation.2×10~6 MSC was injected through tail vein at the 15~(th) day and 30~(th) day after transplantation,respectively;(4) CsA treatment group(group D_4):Lewis-Wistar,CsA 2mg/kg·d was injected into abdominal cavity from after transplantation to the end of investigation.The investigation time was 120 days after transplantation.On 120~(th) day after transplantation,the allografts were harvested for pathological examination to analyze the depth of artery wall and the infiltration of collagenous fiber in cardiac muscle by MASSON staining.
Results:All recipients and transplanted hearts survived well to the investigating ends.The mean ratio of artery wall depth to artery diameter(%): group A_4 was 19.68±2.06,group B_4 was 29.14±1.98,group C_4 was 29.88±2.28 and group D_4 was 39.82±1.84.Group B_4 and group C_4 is similar,P＞0.05.The infiltration area of collagenous fiber to cardiac muscle(%):group A_4 was 8.76±1.56,group B_4 was 17.98±2.40,group C_4 was 19.50±2.24 and group D_4 was 17.64±2.47.Group A_4 was less infiltrated with collagenous fiber than the other 3 groups,P＜0.01.Group B_4,group C_4 and group D_4 were similar in the infiltration of collagenous fiber,P＞0.05.
Conclusions:Intravenous infusion with MSC from recipients did not reduce the level of chronic rejection of rat cardiac transplantation.
目的:建立成功率较高的大鼠颈部异位心脏移植模型。
方法:采用自制的套管连接血管建立移植心脏血流通路:移植心脏无名动脉连接大鼠右颈总动脉,移植心脏左肺动脉连接大鼠右颈外静脉,建立大鼠颈部心脏移植模型。术后24小时移植心脏正常跳动视为移植成功。
结果:建模成功率为88%(30/34)。
结论:成功应用套管法建立了大鼠颈部心脏移植模型。
第二部分大鼠骨髓间充质干细胞的体外分离、培养与鉴定
目的:建立稳定的大鼠骨髓间充质干细胞(Mesenchymal stem cells,MSC)体外分离、培养、鉴定方法。
方法:选用1月龄雄性清洁级Wistar大鼠,处死消毒后取其胫骨和股骨,用含15%胎牛血清DMEM冲洗骨髓腔,收集冲洗液,采用密度梯度离心法分离获取细胞,培养后对贴壁细胞进行传代培养。取第3代生长状态良好的细胞,以流式细胞术鉴定细胞表型,并进行冻存复苏实验。
结果:MSC在培养瓶中24h后就有细胞贴壁,第3～4d细胞生长明显,经换液去除未贴壁细胞,传代后细胞生长迅速,约6～8d即可长满培养瓶底,达融合状态,三代后即可得到较为纯化的MSC成纤维样细胞,并至少可传代10代以上,冻存对细胞生长无影响。流式细胞术检测细胞表面分子标志,显示CD11B(-)、CD29(+)、CD34(-)、CD45(-)、CD90(+)、CD106(+)。
结论:通过密度梯度离心及贴壁筛选培养法获取大鼠骨髓MSC的方法简便易行,可提供稳定的大鼠MSC。
第三部分受者同系骨髓间充质干细胞对大鼠心脏移植急性排斥反应的影响
目的:观察受者同系骨髓MSC对大鼠心脏移植急性排斥反应的影响,并探讨MSC的免疫调节机制。
方法:实验动物随机分为2组,每组10只受体,进行Lewis→Wistar颈部心脏移植:(1)空白对照组(A_3组):手术后24h,确定手术成功,即经尾静脉注射3mL0.9%氯化钠注射液;(2)MSC处理组(B_3组):手术后24h,确定手术成功,即经尾静脉注射MSC2×10~6(悬浮在3mL0.9%氯化钠注射液中)。术后一周,每组随机取4只大鼠,取下腔静脉血及移植物进行组织学及免疫学检查。检测项目:病理学分级,血清IL-2及IL-10,血、移植物CD4~+、CD8~+、CD4~+CD25~(high)、CD4~+CD25~(high)foxp3~+T细胞占总淋巴细胞的比例,及CD4~+/CD8~+比值。其余6只用以继续观察移植物存活时间。另外再建立2只大鼠心脏移植模型,术后24小时,经尾静脉注射表达绿色荧光蛋白的同系MSC(MSC~(GFfP))2×10~6,术后7天取移植心脏,冰冻切片,荧光显微镜下观察移植物内荧光细胞的分布情况。
结果:(1)A_3组大鼠移植心脏存活7.2±1.3d,B_3组大鼠移植心脏存活14.8±2.9d。P＜0.01。(2)血清IL-2:A_3组为233.99±30.19pg/mL,B_3组为249.11±20.34 pg/mL,P＞0.1;血清IL-10:A_3组为81.44±11.01 pg/mL,B_3组为158.39±18.70 pg/mL,P＜0.01。(3)病理学分级,A_3组3B级1例,4级3例;B_3组2级1例,3A级2例,3B级1例,B_3组病理分级总体较A_3组低。(4)大鼠血中CD4~+/CD8~+值、CD4~+CD25~(high)T细胞占总淋巴细胞的比例、CD4~+CD25~(high)Foxp3~+T细胞占总淋巴细胞的比例,B_3组都明显高于A_3组,差异有统计学意义(P＜0.01)。(5)移植心脏中CD4~+/CD8~+值两组之间无显著性差异,CD4~+CD25~(high)T细胞占总淋巴细胞的比例、CD4~+CD25~(high)Foxp3~+T细胞占总淋巴细胞的比例,B_3组都明显高于A_3组,差异有统计学意义(P＜0.01)。(6)心脏移植术后24h,经尾静脉向受体大鼠注射同系MSC~(GFP)后6天,荧光显微镜下观察移植心脏冰冻切片可见荧光细胞在移植心脏表面分布较集中,并向心肌组织浸润,形态及分布类似心肌细胞。
结论:静脉注射受者同系骨髓MSC,可以延长大鼠颈部移植心脏的存活时间,减轻急性排斥反应的程度。
第四部分受者同系骨髓间充质干细胞对大鼠心脏移植慢性排斥反应的影响
目的:观察受者同系骨髓MSC对大鼠心脏移植慢性排斥反应的影响。
方法:实验共设4组,每组5只受体大鼠,行颈部心脏移植手术:(1)同系移植组(A_4组):Wistar→Wistar,CsA2mg/kg·d腹腔注射14天;(2)慢性排斥组(B_4组):Lewis→Wistar,CsA 2mg/kg·d腹腔注射14天;(3)MSC处理组(C_4组):Lewis→Wistar,CsA 2mg/kg·d腹腔注射14天,术后第15天、第30天分别经尾静脉注射MSC2×10~6;(4)单纯CsA组(D_4组):Lewis→Wistar,CsA 2mg/kg·d腹腔注射至观察终点。观察终点为术后120天。届时,取移植心做病理检查,MASSON染色,分析心脏动脉管壁增厚情况及心肌间质胶原增生情况。
结果:所有受体及移植物均良好存活至观察终点。移植心脏内动脉管壁增厚比例(%):A_4组19.68±2.06,B_4组29.14±1.98,C_4组29.88±2.28,D_4组39.82±1.84。B_4-C_4组之间差异无统计学意义(P＞0.05)。胶原增生比例(%):A_4组8.76±1.56,B_4组17.98±2.40,C_4组19.50±2.24,D_4组17.64±2.47。A_4组纤维增生较其它各组明显减轻,差异有统计学意义(P＜0.01);B_4、C_4、D_4各组之间差异无统计学意义(P＞0.05)。
结论:早期应用CsA2周后,静脉输注受者同系MSC未能减轻移植心脏慢性排斥反应的程度。
PartⅠ
Establishment of a Cervical Heterotopic Cardiac Transplantation Model of Rats
Objectives:To establish a modified model of rat cervical heterotopic cardiac transplantation for high achievement ratio.
Methods:A right cervical heterotopic cardiac transplantation model of rats was established.The allograft blood circulation was established with cuff technique using home-made cannulas.Through the cannulas,the donor innominate artery was anastomosed to the recipient's right common carotid artery and donor left pulmonary artery to the recipient's external jugular vein.The successful standard of transplantation was the transplanted heart could beat rhythmically over 24 hours.
Results:Successful rate of heterotopic cardic transplantation is 88%(30/34).
Conclusions:A modified model of rat cervical heterotopic cardiac transplantation was established with cuff technique.
PartⅡ
Isolation,Culturing and Identification of Rat MSC From Bone Marrow in vitro
Objectives:To establish the methods for the isolation,culturing and identification of rat MSC from bone marrow in vitro.
Methods:One month old male Wistar rats were killed to get the tibias and femurs.After the long bones were dissected from rats,the marrows were flushed out with DMEM medium(supplemented with 15%fetal bovine serum) under aseptic condition and purified by Percoll gradient centrifugation to get the mononuclear cells.After the mononuclear cells were cultured,the adherent cells were chosen for serial subcultivation.The third generation cells were harvested and the cell phenotypes were identified by flow cytometry.
Results:The mesenchymal stem cells were adhered to plastic surface within 24h.The cell growth was obvious on the 3～4 days.Nonadherent cells were removed by changing the culture medium.After passage,the cells gown rapidly to fill the floor of cell culture flasks and achieved confluence within 6～8 days. Purified MSC fibroblast-like cells could be harvested after 3 generations.There was no obvious influence to cell growth when reserved in frozen condition.The cells could passage for at least 10 generations.The cell phenotypes identified by flow cytometry showed CD29(+)、CD34(-)、CD45(-)、CD11B(-)、CD90 (+)、CD106(+).
Conclusions:The methods of obtaining rat MSC with density gradient centrifugation and adherence cultivation was convenient,and could provide immortalized rat MSC lines.
PartⅢEffects of Bone Marrow Mesenchymal Stem Cells Derived from Recipients on the Acute Rejection in Rat Cardiac Transplantation Models
Objectives:To investigate the effects of MSC derived from recipients' bone marrow on the acute rejection of rat cardiac transplantation and study the possible underlying mechanisms.
Methods:Twenty Wistar rats beating transplanted heart from Lewis rats were divided randomly into 2 groups(10 rats each group ):(1)Control group (group A3):3mL 0.9%NaCl solution was injected through tail vein at 24h after heart transplantation.(2) Treatment group(group B_3):2×10~6 MSC in 3mL 0.9%NaCl solution was injected through tail vein at 24h after heart transplantation. One week after transplantation,4 rats randomly from each group were anaesthetized to get blood from inferior canal vein and allografts.Grafts pathology was studied.Serum levels of IL-2 and IL-10 was detected by method of ELISA.Flow cytometry was used to detect the ratio of CD4~+ T cells,CD8~+ T cells, CD4~+CD25~(high) T cells and CD4~+CD25~(high)foxp3~+ T cells in lymphocytes in the blood and grafts.The rest 6 rats in each group were observed survival time of grafts.Two other cardiac transplantation models were established.At 24h after transplantation,2×10~6 MSC~(GFP) were injected throug tail vein,respectively.The two grafts were harvested on 7~(th) day after transplantation to get frozen sections for observing the fluorescence cells in grafts.
Results:(1) The survival time of allografts:group A_3 was 7.2±1.3d,group B_3 was 14.8±2.9d.P＜0.01.(2)Concentrations of serum IL-2:group A_3 was 233.99±30.19pg/mL,group B_3 was 249.11±20.34 pg/mL,P＞0.1;IL-10:group A_3 was 81.44±11.01 pg/mL,group B_3 was 158.39±18.70 pg/mL,P＜0.01. (3)Pathology grade:group A_3:1 case was Grade 3B,3 cases were Grade 4;group B_3:1 case was Grade 2,2 cases were Grade 3A,1 case was Grade 3B.(4) Ratios of CD4~+/CD8~+,CD4~+CD25~(high) T cells/total lymphocytes and CD4~+CD25~(high)Foxp3~+ T cells/total lymphocytes in blood:group B3 was higher than group A_3,P＜0.01.(5) Ratios of CD4~+/CD8~+ in allografts were similar in two groups,P＞0.1;CD4~+CD25_(high)T cells/total lymphocytes and CD4~+CD25~(high)Foxp3~+ T cells/total lymphocytes in allografts:group B_3 was higher than group A_3, P＜0.01.(6) Fluorescence cells could be observed to concentrate to the surface of allografts,some cells had infiltrated into cardiac muscle and their shapes and distributions were just like cardiac muscle.
Conclusions:Intravenous infusion with MSC from recipients could prolong the survival time of transplanted heart and inhibit acute rejection.
PartⅣ
Effects of Bone Marrow Mesenchymal Stem Cells Derived from Recipients on the Chronic Rejection in Rat Cardiac Transplantation Models
Objectives:To observe the effects of mesenchymal stem cells derived from recipients' bone marrow on the chronic rejection of rat cardiac transplantation.
Methods:Twenty rats bearing transplanted hearts were divided randomly into 4 groups(5 rats each group):(1)Homologous transplantation group(group A_4):Wistar-Wistar,CsA 2mg/kg·d was injected into abdominal cavity for 14 days after transplantation;(2)Chronic rejection group(group B_4):Lewis-Wistar,CsA 2mg/kg·d was injected into abdominal cavity for 14 days after transplantation; (3)MSC treatment group(group C_4):Lewis-Wistar,CsA 2mg/kg·d was injected into abdominal cavity for 14 days after transplantation.2×10~6 MSC was injected through tail vein at the 15~(th) day and 30~(th) day after transplantation,respectively;(4) CsA treatment group(group D_4):Lewis-Wistar,CsA 2mg/kg·d was injected into abdominal cavity from after transplantation to the end of investigation.The investigation time was 120 days after transplantation.On 120~(th) day after transplantation,the allografts were harvested for pathological examination to analyze the depth of artery wall and the infiltration of collagenous fiber in cardiac muscle by MASSON staining.
Results:All recipients and transplanted hearts survived well to the investigating ends.The mean ratio of artery wall depth to artery diameter(%): group A_4 was 19.68±2.06,group B_4 was 29.14±1.98,group C_4 was 29.88±2.28 and group D_4 was 39.82±1.84.Group B_4 and group C_4 is similar,P＞0.05.The infiltration area of collagenous fiber to cardiac muscle(%):group A_4 was 8.76±1.56,group B_4 was 17.98±2.40,group C_4 was 19.50±2.24 and group D_4 was 17.64±2.47.Group A_4 was less infiltrated with collagenous fiber than the other 3 groups,P＜0.01.Group B_4,group C_4 and group D_4 were similar in the infiltration of collagenous fiber,P＞0.05.
Conclusions:Intravenous infusion with MSC from recipients did not reduce the level of chronic rejection of rat cardiac transplantation.
引文
[1]Di Nicola M,Carlo-Stella C,Magni M,et al.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood.2002,99:3838-3843.
[2]Glennie S,Soeiro I,Dyson PJ,et al.Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.Blood.2005,105:2821-2827.
[3]Bartholomew A,Sturgeon C,Siatskas M,et al.Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol.2002,30:42-48.
[4]Han Q,Deng W,Zhao RC,et al.Allogeneic adult stem cells establish long-term residence in recipient tissues and facilitate skin transplantation.Exp Hematol.2003,31:158-163.
[5]Majumdar MK,Keane-Moore M,Buyaner D,et al.Characterization and functionality of cell surface molecules on human mesenchymal stem cells.J Biomed Sci.2003,10:228-241.
[6]Arinzeh TL,Peter SJ,Archambault MP,et al.Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect.J Bone Joint Surg Am.2003,85-A(10):1927-1935.
[7]Le-Blanc K,Rasmusson I,Sundberg B,et al.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.Lancet.2004,363:1439-1441.
[8]Lazarus HM,Curtin P,Devine SM,et al.Role of mesenchymal stem cells (MSC) in allogeneic transplantation:early phase I clinical results.Blood.2000,392:1691-1698.
[9]Lazarus HM,Koc ON,Devine SM,et al.Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant.2005,11:389-398.
[1]Abbot CP,Lindsey ES,Creech O,et al.A technique for heart transplantation in the rat.Arch Surg.1964,89:645-652.
[2]Ono K.Improved technique of heart transplantation in rats.J Thorac Cardiovasc Surg.1969,57:645.
[3]Heron I.A technique for accessory cervical heart transplantation in rabbits and rats.Acta Pathol Microbiol Immunol Scand.1971,79:366.
[4]Yukihiro T,Zhang QW,Masahiro Y,et al.Improved technique of heterotopic cervical heart transplantation in mice.Transplantation,1997,64:1598-1601.
[5]李平,张凯伦,高思海.套管改良法建立大鼠颈部心脏移植模型.心肺血管病杂志.2005,24:174-175.
[6]王亦斌,于立新,王志鹏,等.大鼠心脏移植急性排斥反应动物模型的建立.中国实验动物学报.2006,14:56-58.
[7]Billingham ME,Cary NRB,Hammond ME,et al.A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection.J Heart Transplant.1990,9:587-593.
[8]庄聪文,翁向群,黄盛东,等.大鼠颈部异位心脏移植急性排斥反应的早期病理变化.东南国防医学.2005,7(3):181-183.
[9]范钦明,廖崇先,单忠贵,等.大鼠颈部和腹腔心脏移植模型建立的体会和比较.滨州医学院学报.2006,29:173-175.
[10]施新猷主编.现代医学实验动物学.北京:人民军医出版社,2000:82-93.
[1]Friedenstein A,Kuralesova AI.Osteogenic precursor cells of bone marrow in radiation chimeras.Transplantation.1971,12:99-108.
[2]Campagnoli C,Roberts IA,Kumar S,Bennett PR,Bellanruono I,Fisk NM.Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood,liver,and bone marrow.Blood.2001,98:2396-2402.
[3]De Ugarte DA,Morizono K,Elbarbary A,et al.Comparison of multi-lineage cells from human adipose tissue and bone marrow.Cells Tissues Organs.2003,174:101-109.
[4]Deryugina EI,Muller-Sieburg CE.Stromal cells in long term cultures:keys to the elucidation of hematopoietic development.Crit Rev Immunol.1993,13:115-119.
[5]Herzog EL,Chai L,Krause DS.Plasticity of marrow-derived stem cells.Blood.2003,102:3483-3493.
[6]Barry F,Boynton R,Murphy M,et al.The SH-3 and SH-4antibodies recognized distinct epitopes on CD73 from human mesenchymal stem cells.Biochem Biophys Res Commun.2001,289:519-524.
[7]Niemeyer P,Seckinger A,Simank HG,et al.Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes:an in vitro study.Orthopade.2004,33:1346-1353.
[8]Deans RJ,Moseley AB.Mesenchymal stem cells:biology and potential clinical uses.Exp Hematol.2000,28:875-884.
[9]Gronthos S,Zannettino AC,Hay SJ et al.Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow.J Cell Sci.2003,116:1827-1835.
[10]Baddoo M,Hill K,Wilkinson R.Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection.J Cell Biochem.2003,89:1235-1249.
[1]Zhou HP,Yi DH,Yu SQ,et al.Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft.Transplant Proc.2006,38:3046-3051.
[2]Lazarus HM,Koc ON,Devine SM,et al.Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant.2005,11:389-398.
[3]Beyth S,Borovsky Z,Mevorach D,et al.Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness.Blood.2005,105:2214-2219.
[4]万赤丹,程锐,王宏博,等.脂肪来源间充质干细胞对大鼠肝移植的免疫调节作用.中华实验外科杂志.2007,24:279-281.
[5]Batten P,Sarathchandra P,Antoniw JW,et al.Human masenchynal stem cells induce T cell anergy and downregulate T cell allo-responses via the Th2pathway:relevance to tissue engineering human heart valves.Tissue Eng.2006,12:2263-2273.
[6]陈慰峰主编.医学免疫学.人民卫生出版社.2005年,第4版:106-107.
[7]Roncarolo MG,Gregori S,Battaglia M,et al.Interleukin-10-secreting type 1regulatory T cells in rodents and humans.Immunol Rev.2006,212:28-50.
[8]Maitra B,Szekely E,Gjini K et al.Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation.Bone Marrow Transplant.2004,33:597-604.
[9]Potian JA,Aviv H,Ponzio NM,et al.Veto-like activity of mesenchymal stem cells:functional discrimination between cellular responses to alloantigens and recall antigens.J Immunol.2003,171:3426-3434.
[10]Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains(CD25).Breakdown of single mechanism of self-tolerance causes various autoimmune diseases.J Immunol.1995,155:1151-1164.
[11]Sakaguchi S,Sakaguchi N,Shimizu J,et al.Immunologic tolerance maintained by CD25~+CD4~+ regulatory T cells:their common role in controlling autoimmunity,tumor immunity,and transplantation tolerance.J Immunol Rev.2001,182:18-24.
[12]Claire T,Fiona P.Regulatory T cells.Curr Opin Organ Transpl.2004,4:408-415.
[13]Waldmann H,Chen TC,Graca L,et al.Regulatory T cells in transplantation.Semin Immunol.2006,18:111-118.
[14]Beecher-Allan C,Brown JA,Freeman GJ,et al.CD4~+CD25~(high) regulatory cells in human peripheral blood.J Immunol.2001,167:1245-1253.
[15]Cobbold SP,Nolan KF,Graca L,et al.Regulatory Tcells and dendritic cells in transplantation tolerance:molecular markers and mechanisms.Immunol Rev.2003,196:109-124.
[16]Beyer M,Schultze JL.Regulatory T cells in cancer.Blood.2006,108:804-811.
[17]Piccirillo CA,Shevach EM.Cutting edge:control of CD8~+ T cell activation by CD4~+CD25~+ immunoregulatory cells.J Immunol.2001,167:1137-1140.
[18]Cassis L,Aiello S,Noris M,et al.Natural versus adaptive regulatory T cells.Contrib Nephrol.2005,146:121-127.
[19]Zhang Y,Liu C,Yang XM,et al.Role and mechanisms of CD4~+CD25~+.regulatory T cells in the induction and maintenance of transplantation tolerance.Transplant Immunol.2007,17:120-127.
[20]Ng WF,Duggan PJ,Ponchel F,et al.Human CD4(+)CD25(+) cells:a naturally occurring population of regulatory T cells.Blood.2001,98:2736-2744.
[21]陈慰峰主编.医学免疫学.人民卫生出版社,2005年,第4版:108.
[22]Shevach E.Regulatory Tcells in autoimmunity.Annu Rev Immunol.2000,18:423-449.
[23]Velthuis JH,Mol WM,Weimar W,et al.CD4~+CD25~(bright) regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients.Am J Transplant.2006,6:2955-2964.
[24]Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3.Science.2003,299:1057-1061.
[25]Kingsley CI,Karim M,Bushell AR,et al.CD25+CD4+ regulatory T cells prevent graft rejection:CTLA-4-and IL-10-dependent immunoregulation of alloresponses.J Immunol.202,168:1080-1086.
[26]Fontenot JD,Rasmussen JP,Gavin MA.A function for interleukin 2 in Foxp3-expressing regulatory T cells.Nat Immunol.2005,6:1142-1151.
[27]Liechty KW,Machenzie TC,Shaaban AF,et al.Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in uterotransplantation in sheep.Nat Med.2000,6:1282-1286.
[28]Niu IX,Zheng M,Cao F,et al.Migration and differentiation of exogenous rat mesenchymal stem cells engrafted into normal and injured hearts of rats.Natl Med J China.2004,84:38-42.
[29]Gordon D,Wu MD,Michael E,et al.Contribution of mesenchymal progenitor cells to tissue repair in rat cardiac allografts undergoing chronic rejection.J Heart Lung Transplant.2005,24:2160-68.
[30]Uccelli A,Pistoia V,Moretta L.Mesenchymal stem cells:a new strategy for immunosuppression?Trends Immunol.2007,28:219-226.
[31]Hematti P.Role of mesenchymal stromal cells in solid organ transplantation.Transplant Rev.2008,22:262-273.
[1]Hayry P,Aavik E,Savolainen H.Mechanisms of chronic rejection.Transplant Proc,1999,31(Suppl 7A):5S-8S.
[2]Billingham ME.Pathology of transplantation.In:Solez K,Racusen LC,Billingham ME,eds.Solid organ transplant rejection.1th ed.New York:Marcel Dekker,1996:137-159.
[3]Peiman Hematti.Role of mesenchymal stromal cells in solid organ transplantation.Transplantation.2008,22:262-273.
[1]Friedenstein AJ,Petrakova KV,Kurolesova AI,et al.Heterotopic of bone marrow.Analysis of precursor cells for osteogenic and hematopoietic tissues.Transplantation.1968,6:230-247.
[2]Campagnoli C,Roberts IA,Kumar S,et al.Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood,liver,and bone marrow.Blood.2001,98:2396-2402.
[3]De Ugarte DA,Morizono K,Elbarbary A et al.Comparison of multi-lineage cells from human adipose tissue and bone marrow.Cells Tissues Organs.2003,174:101-109.
[4]Simmons PJ,Torok-Storb B.Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody,STRO-1.Blood.1991,78:55-62.
[5]Gronthos S,Zannettino AC,Hay SJ et al.Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow.J Cell Sci.2003,116:1827-35.
[6]Tremain N,Korkko J,Ibberson D,et al.MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages.Stem Cells.2001,19:408-418.
[7]Gao J,Dennis JE,Muzic RF,et al.The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion.Cells Tissues Organs.2001,169:12-20.
[8]Chapel A,Bertho JM,Bensidhoum M et al.Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome.J Gene Med.2003,5:1028-1038.
[9]Devine SM,Cobbs C,Jennings M,et al.Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood.2003,101:2999-3001.
[10]Crevensten G,Walsh AJ,Ananthakrishnan D et al.Intervertebral disc cell therapy for regeneration:mesenchymal stem cell implantation in rat intervertebral discs.Ann Biomed Eng.2004,32:430-434.
[11]Chamberlain JR,Schwarze U,Wang PR et al.Gene targeting in stem cells from individuals with osteogenesis imperfecta.Science.2004,303:1198-1201.
[12]Toma C,Pittenger MF,Cahill KS,et al.Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.Circulation.2002,105:93-98.
[13]Murphy JM,Fink DJ,Hunziker EB,et al.Stem cell therapy in a caprine model of osteoarthritis.Arthritis Rheum.2003,48:3464-3474.
[14]Sugaya K.Potential use of stem cells in neuroreplacement therapies for neurodegenerative diseases.Int Rev Cytol.2003,228:1-30.
[15]Maitra B,Szekely E,Gjini K et al.Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation.Bone Marrow Transplant.2004,33:597-604.
[16]Bartholomew A,Sturgeon C,Siatskas M et al.Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol.2002,30:42-48.
[17]Le Blanc K,Tammik L,Sundberg B,et al.Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.Scand J Immunol.2003,57:11-20.
[18]Tse WT,Pendleton JD,Beyer WM,et al.Suppression of allogeneic T-cell proliferation by human marrow stromal cells:implications in transplantation.Transplantation.2003,75:389-397.
[19]Togel F,Hu Z,Weiss K,et al.Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms.Am J Physiol Renal Physiol.2005,289:31-42.
[20]Zappia E,Casazza S,Pedemonte E et al.Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.Blood.2005,106:1755-1761.
[21]Conget PA,Minguell JJ.Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells.J Cell Physiol.1999,181:67-73.
[22]Le Blanc K,Tammik L,Zetterberg E,et al.HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.Exp Haematol.2003,31:890-896.
[23]Klyushnenkova E,Mosca JD,Zernetkina V et al.T cell responses to allogeneic human mesenchymal stem cells:immunogenicity,tolerance,and suppression.J Biomed Sci.2005,12:47-57.
[24]Potian JA,Aviv H,Ponzio NM,et al.Veto-like activity of mesenchymal stem cells:functional discrimination between cellular responses to alloantigens and recall antigens.J Immunol.2003,171:3426-3434.
[25]Beyth S,Borovsky Z,Mevorach D et al.Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood.2005,105:2214-2219.
[26]Le Blanc K,Rasmusson I,G(?)therstrom C et al.Mesenchymal stem cells inhibit the expression of CD25(interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes.Scand J Immunol.2004,60:307-315.
[27]Rasmusson I,Ringden O,Sundberg B,et al.Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes,but not activated cytotoxic T lymphocytes or natural killer cells.Transplantation.2003,76:1208-1213.
[28]Angoulvant D,Clerc A,Benchalal S et al.Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens.Biorheology.2004,41:469-476.
[29]Di Nicola M,Carlo-Stella C,Magni M et al.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood.2002,99:3838-3843.
[30]Rasmusson I,Ringden O,Sundberg B,et al.Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms.Exp Cell Res.2005,305:33-41.
[31]Liu J,Lu XF,Wan L et al.Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbredline.Transplant Proc.2004,36:3272-3275.
[32]Glennie S,Soeiro I,Dyson PJ,et al.Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.Blood.2005,105:2821-2827.
[33]Blazar BR,Taylor PA.Regulatory T cells.Biol Blood Marrow Transplant.2005,11:46-49.
[34]Taylor PA,Lees CJ,Blazar BR.The infusion of ex vivo activated and expanded CD4~+CD25~+ immune regulatory cells inhibits graft-versus-host disease lethality.Blood.2002,99:3493-3499.
[35]Aggarwal S,Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood.2005,105:1815-1822.
[36]Maccario R,Podesta M,Moretta A et al.Interaction of human mesenchymal stem cells with cells involved in alloantigenspecific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype.Haematologica.2005,90:516-525.
[37]Groh ME,Maitra B,Szekely E,et al.Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells.Exp Hematol.2005,33:928-934.
[38]Feinberg K,Silvestri G.T(S) cells and immune tolerance induction:a regulatory renaissance?Nat Immunol.2002,3:215-217.
[39]Le Blanc K,Rasmusson I,Sundberg B et al.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.Lancet.2004,363:1439-1441.
[40]Meisel R,Zibert A,Laryea M,et al.Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.Blood.2004,103:4619-4621.
[41]Arikawa T,Omura K,Morita I.Regulation of bone morphogenetic protein-2expression by endogenous prostaglandin E2 in human mesenchymal stem cells.J Cell Physiol.2004,200:400-406.
[42]Corcione A,Benvenuto F,Ferretti E et al.Human mesenchymal stem cells modulate B-cell functions.Blood.2006,107:367-372.
[43]Friedenstein A,Kuralesova AI.Osteogenic precursor cells of bone marrow in radiation chimeras.Transplantation.1971,12:99-108.
[44]Jiang XX,Zhang Y,Liu B et al.Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.Blood.2005,105:4120-4126.
[45]Svensson M,Maroof A,Ato M,et al.Stromal cells direct local differentiation of regulatory dendritic cells.Immunity.2004,21:805-816.
[46]Spaggiari GM,Capobianco A,Becchetti S,et al.Mesenchymal stem cell-natural killer cell interactions:evidence that activated NK cells are capable of killing MSCSS whereas MSCSS can inhibit IL-2-induced NK-cell proliferation.Blood.2006,107:1484-1490.
[47]Rasmusson I,Le Blanc K,Sundberg B,et al.Mesenchymal stem cells stimulate antibody secretion in human B cells.Scand J Immunol.2007,65:336-343.
[48]邓为民,韩钦,葛薇等.骨髓源间充质干细胞在异基因小鼠免疫器官内的分布及其免疫功能调节作用.中国免疫学杂志.2004,20:40-45.
[49]Wang JW,Liu YB,Xu B,et al.The study on immunomodulation of donor mesenchymal stem cells on discordant liver xenotransplantation.Zhonghua Waike Zazhi.2005,43:928-934.
[50]Eliopoulos N,Stagg J,Lejeune L,et al.Allogeneic marrow stromal cells are immune rejected by MHC class Ⅰ-and class Ⅱ-mismatched recipient mice.Blood.2005,106:4057-4065.
[51]Fouillard L,Bensidhoum M,Bories D,et al.Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma.Leukemia.2003,17:474-476.
[52]Le Blanc K,Gotherstrom C,Ringden O,et al.Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta.Transplantation.2005,79:1607-1614.
[53]Koc ON,Peters C,Aubourg P,et al.Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases.Exp Hematol.1999,27:1675-1681.
[54]Krivit W,Shapiro EG,Lockman LA,et al.Bone marrow transplantation:treatment for globoid cell leukodystrophy,metachromatic leukodystrophy,adrenoleukodystrophy and Hurler syndrome.In:Moser HW,Vinken PJ,Bruyn GW,eds.Handbook of Clinical Neurology.Amsterdam:Elsevier Science.1996,87-106.
[55]Koc ON,Day J,Nieder M,et al.Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy(MLD) and Hurler syndrome(MPS-IH).Bone Marrow Transplant.2002,30:215-222.
[56]Horwitz EM,Prockop DJ,Gordon PL,et al.Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta.Blood.2001,97:1227-1231.
[57]Horwitz EM,Gordon PL,Koo WK,et al.Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta:Implications for cell therapy of bone.Proc Natl Acad Sci U S A.2002,99:8932-8937.
[58]Lee ST,Jang JH,Cheong JW,et al.Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype.Br J Haematol.2002,118:1128-1131.
[59]Le Blanc K,Gustafsson B,Remberger,M et al.Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.Leukemia.2007,21:1733-1738.
[60]Lazarus HM,Koc ON,Devine SM,et al.Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant.2005,11:389-398.
[61]Cahill RA,Jones OY,Klemperer,M et al.Replacement of recipient stromal/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells.Biol Blood Marrow Transplant.2004,10:709-717.
[62]Ringd(?)n O,Uzunel M,Rasmusson I,et al.Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.Transplantation.2006,81:1390-1397.
[63]Le Blanc K,Frassoni F,Uzunel M,et al.Mesenchymal stem cells for treatment of severe graft-versus-host disease.Blood.2006,108:753.
[64]Ringden O,Uzunel M,Sundberg B,et al.Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis,pneumomediastinum and perforated colon.Leukaemia.2007,21:2271-2276.
[65]Wu GD,Nolta JA,Jin YS,et al.Migration of mesenchymal stem cells to heart allografts during chronic rejection.Transplantation.2003,75:679-685.
[66]Sundin M,Orvell C,Rasmusson I,et al.Mesenchymal stem cells are susceptible to human herpesviruses,but viral DNA cannot be detected in the healthy seropositive individual.Bone Marrow Transplant.2006,37: 1051-1059.
[67]Horowitz MM,Gale RP,Sondel PM et al.Graft-versus-leukemia reactions after bone marrow transplantation.Blood.1990,75:555-562.
[68]Ringden O,Hermans J,Labopin M,et al.The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade Ⅰ acute graft-versus-host disease.Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT).Leuk Lymphoma.1996,24:71-79.
[69]Hematti P.Role of mesenchymal stromal cells in solid organ transplantation.Transplant Rev.2008,22:262-273.
[2]Glennie S,Soeiro I,Dyson PJ,et al.Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.Blood.2005,105:2821-2827.
[3]Bartholomew A,Sturgeon C,Siatskas M,et al.Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol.2002,30:42-48.
[4]Han Q,Deng W,Zhao RC,et al.Allogeneic adult stem cells establish long-term residence in recipient tissues and facilitate skin transplantation.Exp Hematol.2003,31:158-163.
[5]Majumdar MK,Keane-Moore M,Buyaner D,et al.Characterization and functionality of cell surface molecules on human mesenchymal stem cells.J Biomed Sci.2003,10:228-241.
[6]Arinzeh TL,Peter SJ,Archambault MP,et al.Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect.J Bone Joint Surg Am.2003,85-A(10):1927-1935.
[7]Le-Blanc K,Rasmusson I,Sundberg B,et al.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.Lancet.2004,363:1439-1441.
[8]Lazarus HM,Curtin P,Devine SM,et al.Role of mesenchymal stem cells (MSC) in allogeneic transplantation:early phase I clinical results.Blood.2000,392:1691-1698.
[9]Lazarus HM,Koc ON,Devine SM,et al.Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant.2005,11:389-398.
[1]Abbot CP,Lindsey ES,Creech O,et al.A technique for heart transplantation in the rat.Arch Surg.1964,89:645-652.
[2]Ono K.Improved technique of heart transplantation in rats.J Thorac Cardiovasc Surg.1969,57:645.
[3]Heron I.A technique for accessory cervical heart transplantation in rabbits and rats.Acta Pathol Microbiol Immunol Scand.1971,79:366.
[4]Yukihiro T,Zhang QW,Masahiro Y,et al.Improved technique of heterotopic cervical heart transplantation in mice.Transplantation,1997,64:1598-1601.
[5]李平,张凯伦,高思海.套管改良法建立大鼠颈部心脏移植模型.心肺血管病杂志.2005,24:174-175.
[6]王亦斌,于立新,王志鹏,等.大鼠心脏移植急性排斥反应动物模型的建立.中国实验动物学报.2006,14:56-58.
[7]Billingham ME,Cary NRB,Hammond ME,et al.A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection.J Heart Transplant.1990,9:587-593.
[8]庄聪文,翁向群,黄盛东,等.大鼠颈部异位心脏移植急性排斥反应的早期病理变化.东南国防医学.2005,7(3):181-183.
[9]范钦明,廖崇先,单忠贵,等.大鼠颈部和腹腔心脏移植模型建立的体会和比较.滨州医学院学报.2006,29:173-175.
[10]施新猷主编.现代医学实验动物学.北京:人民军医出版社,2000:82-93.
[1]Friedenstein A,Kuralesova AI.Osteogenic precursor cells of bone marrow in radiation chimeras.Transplantation.1971,12:99-108.
[2]Campagnoli C,Roberts IA,Kumar S,Bennett PR,Bellanruono I,Fisk NM.Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood,liver,and bone marrow.Blood.2001,98:2396-2402.
[3]De Ugarte DA,Morizono K,Elbarbary A,et al.Comparison of multi-lineage cells from human adipose tissue and bone marrow.Cells Tissues Organs.2003,174:101-109.
[4]Deryugina EI,Muller-Sieburg CE.Stromal cells in long term cultures:keys to the elucidation of hematopoietic development.Crit Rev Immunol.1993,13:115-119.
[5]Herzog EL,Chai L,Krause DS.Plasticity of marrow-derived stem cells.Blood.2003,102:3483-3493.
[6]Barry F,Boynton R,Murphy M,et al.The SH-3 and SH-4antibodies recognized distinct epitopes on CD73 from human mesenchymal stem cells.Biochem Biophys Res Commun.2001,289:519-524.
[7]Niemeyer P,Seckinger A,Simank HG,et al.Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes:an in vitro study.Orthopade.2004,33:1346-1353.
[8]Deans RJ,Moseley AB.Mesenchymal stem cells:biology and potential clinical uses.Exp Hematol.2000,28:875-884.
[9]Gronthos S,Zannettino AC,Hay SJ et al.Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow.J Cell Sci.2003,116:1827-1835.
[10]Baddoo M,Hill K,Wilkinson R.Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection.J Cell Biochem.2003,89:1235-1249.
[1]Zhou HP,Yi DH,Yu SQ,et al.Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft.Transplant Proc.2006,38:3046-3051.
[2]Lazarus HM,Koc ON,Devine SM,et al.Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant.2005,11:389-398.
[3]Beyth S,Borovsky Z,Mevorach D,et al.Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness.Blood.2005,105:2214-2219.
[4]万赤丹,程锐,王宏博,等.脂肪来源间充质干细胞对大鼠肝移植的免疫调节作用.中华实验外科杂志.2007,24:279-281.
[5]Batten P,Sarathchandra P,Antoniw JW,et al.Human masenchynal stem cells induce T cell anergy and downregulate T cell allo-responses via the Th2pathway:relevance to tissue engineering human heart valves.Tissue Eng.2006,12:2263-2273.
[6]陈慰峰主编.医学免疫学.人民卫生出版社.2005年,第4版:106-107.
[7]Roncarolo MG,Gregori S,Battaglia M,et al.Interleukin-10-secreting type 1regulatory T cells in rodents and humans.Immunol Rev.2006,212:28-50.
[8]Maitra B,Szekely E,Gjini K et al.Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation.Bone Marrow Transplant.2004,33:597-604.
[9]Potian JA,Aviv H,Ponzio NM,et al.Veto-like activity of mesenchymal stem cells:functional discrimination between cellular responses to alloantigens and recall antigens.J Immunol.2003,171:3426-3434.
[10]Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains(CD25).Breakdown of single mechanism of self-tolerance causes various autoimmune diseases.J Immunol.1995,155:1151-1164.
[11]Sakaguchi S,Sakaguchi N,Shimizu J,et al.Immunologic tolerance maintained by CD25~+CD4~+ regulatory T cells:their common role in controlling autoimmunity,tumor immunity,and transplantation tolerance.J Immunol Rev.2001,182:18-24.
[12]Claire T,Fiona P.Regulatory T cells.Curr Opin Organ Transpl.2004,4:408-415.
[13]Waldmann H,Chen TC,Graca L,et al.Regulatory T cells in transplantation.Semin Immunol.2006,18:111-118.
[14]Beecher-Allan C,Brown JA,Freeman GJ,et al.CD4~+CD25~(high) regulatory cells in human peripheral blood.J Immunol.2001,167:1245-1253.
[15]Cobbold SP,Nolan KF,Graca L,et al.Regulatory Tcells and dendritic cells in transplantation tolerance:molecular markers and mechanisms.Immunol Rev.2003,196:109-124.
[16]Beyer M,Schultze JL.Regulatory T cells in cancer.Blood.2006,108:804-811.
[17]Piccirillo CA,Shevach EM.Cutting edge:control of CD8~+ T cell activation by CD4~+CD25~+ immunoregulatory cells.J Immunol.2001,167:1137-1140.
[18]Cassis L,Aiello S,Noris M,et al.Natural versus adaptive regulatory T cells.Contrib Nephrol.2005,146:121-127.
[19]Zhang Y,Liu C,Yang XM,et al.Role and mechanisms of CD4~+CD25~+.regulatory T cells in the induction and maintenance of transplantation tolerance.Transplant Immunol.2007,17:120-127.
[20]Ng WF,Duggan PJ,Ponchel F,et al.Human CD4(+)CD25(+) cells:a naturally occurring population of regulatory T cells.Blood.2001,98:2736-2744.
[21]陈慰峰主编.医学免疫学.人民卫生出版社,2005年,第4版:108.
[22]Shevach E.Regulatory Tcells in autoimmunity.Annu Rev Immunol.2000,18:423-449.
[23]Velthuis JH,Mol WM,Weimar W,et al.CD4~+CD25~(bright) regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients.Am J Transplant.2006,6:2955-2964.
[24]Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3.Science.2003,299:1057-1061.
[25]Kingsley CI,Karim M,Bushell AR,et al.CD25+CD4+ regulatory T cells prevent graft rejection:CTLA-4-and IL-10-dependent immunoregulation of alloresponses.J Immunol.202,168:1080-1086.
[26]Fontenot JD,Rasmussen JP,Gavin MA.A function for interleukin 2 in Foxp3-expressing regulatory T cells.Nat Immunol.2005,6:1142-1151.
[27]Liechty KW,Machenzie TC,Shaaban AF,et al.Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in uterotransplantation in sheep.Nat Med.2000,6:1282-1286.
[28]Niu IX,Zheng M,Cao F,et al.Migration and differentiation of exogenous rat mesenchymal stem cells engrafted into normal and injured hearts of rats.Natl Med J China.2004,84:38-42.
[29]Gordon D,Wu MD,Michael E,et al.Contribution of mesenchymal progenitor cells to tissue repair in rat cardiac allografts undergoing chronic rejection.J Heart Lung Transplant.2005,24:2160-68.
[30]Uccelli A,Pistoia V,Moretta L.Mesenchymal stem cells:a new strategy for immunosuppression?Trends Immunol.2007,28:219-226.
[31]Hematti P.Role of mesenchymal stromal cells in solid organ transplantation.Transplant Rev.2008,22:262-273.
[1]Hayry P,Aavik E,Savolainen H.Mechanisms of chronic rejection.Transplant Proc,1999,31(Suppl 7A):5S-8S.
[2]Billingham ME.Pathology of transplantation.In:Solez K,Racusen LC,Billingham ME,eds.Solid organ transplant rejection.1th ed.New York:Marcel Dekker,1996:137-159.
[3]Peiman Hematti.Role of mesenchymal stromal cells in solid organ transplantation.Transplantation.2008,22:262-273.
[1]Friedenstein AJ,Petrakova KV,Kurolesova AI,et al.Heterotopic of bone marrow.Analysis of precursor cells for osteogenic and hematopoietic tissues.Transplantation.1968,6:230-247.
[2]Campagnoli C,Roberts IA,Kumar S,et al.Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood,liver,and bone marrow.Blood.2001,98:2396-2402.
[3]De Ugarte DA,Morizono K,Elbarbary A et al.Comparison of multi-lineage cells from human adipose tissue and bone marrow.Cells Tissues Organs.2003,174:101-109.
[4]Simmons PJ,Torok-Storb B.Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody,STRO-1.Blood.1991,78:55-62.
[5]Gronthos S,Zannettino AC,Hay SJ et al.Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow.J Cell Sci.2003,116:1827-35.
[6]Tremain N,Korkko J,Ibberson D,et al.MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages.Stem Cells.2001,19:408-418.
[7]Gao J,Dennis JE,Muzic RF,et al.The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion.Cells Tissues Organs.2001,169:12-20.
[8]Chapel A,Bertho JM,Bensidhoum M et al.Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome.J Gene Med.2003,5:1028-1038.
[9]Devine SM,Cobbs C,Jennings M,et al.Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood.2003,101:2999-3001.
[10]Crevensten G,Walsh AJ,Ananthakrishnan D et al.Intervertebral disc cell therapy for regeneration:mesenchymal stem cell implantation in rat intervertebral discs.Ann Biomed Eng.2004,32:430-434.
[11]Chamberlain JR,Schwarze U,Wang PR et al.Gene targeting in stem cells from individuals with osteogenesis imperfecta.Science.2004,303:1198-1201.
[12]Toma C,Pittenger MF,Cahill KS,et al.Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.Circulation.2002,105:93-98.
[13]Murphy JM,Fink DJ,Hunziker EB,et al.Stem cell therapy in a caprine model of osteoarthritis.Arthritis Rheum.2003,48:3464-3474.
[14]Sugaya K.Potential use of stem cells in neuroreplacement therapies for neurodegenerative diseases.Int Rev Cytol.2003,228:1-30.
[15]Maitra B,Szekely E,Gjini K et al.Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation.Bone Marrow Transplant.2004,33:597-604.
[16]Bartholomew A,Sturgeon C,Siatskas M et al.Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol.2002,30:42-48.
[17]Le Blanc K,Tammik L,Sundberg B,et al.Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.Scand J Immunol.2003,57:11-20.
[18]Tse WT,Pendleton JD,Beyer WM,et al.Suppression of allogeneic T-cell proliferation by human marrow stromal cells:implications in transplantation.Transplantation.2003,75:389-397.
[19]Togel F,Hu Z,Weiss K,et al.Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms.Am J Physiol Renal Physiol.2005,289:31-42.
[20]Zappia E,Casazza S,Pedemonte E et al.Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.Blood.2005,106:1755-1761.
[21]Conget PA,Minguell JJ.Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells.J Cell Physiol.1999,181:67-73.
[22]Le Blanc K,Tammik L,Zetterberg E,et al.HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.Exp Haematol.2003,31:890-896.
[23]Klyushnenkova E,Mosca JD,Zernetkina V et al.T cell responses to allogeneic human mesenchymal stem cells:immunogenicity,tolerance,and suppression.J Biomed Sci.2005,12:47-57.
[24]Potian JA,Aviv H,Ponzio NM,et al.Veto-like activity of mesenchymal stem cells:functional discrimination between cellular responses to alloantigens and recall antigens.J Immunol.2003,171:3426-3434.
[25]Beyth S,Borovsky Z,Mevorach D et al.Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood.2005,105:2214-2219.
[26]Le Blanc K,Rasmusson I,G(?)therstrom C et al.Mesenchymal stem cells inhibit the expression of CD25(interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes.Scand J Immunol.2004,60:307-315.
[27]Rasmusson I,Ringden O,Sundberg B,et al.Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes,but not activated cytotoxic T lymphocytes or natural killer cells.Transplantation.2003,76:1208-1213.
[28]Angoulvant D,Clerc A,Benchalal S et al.Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens.Biorheology.2004,41:469-476.
[29]Di Nicola M,Carlo-Stella C,Magni M et al.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood.2002,99:3838-3843.
[30]Rasmusson I,Ringden O,Sundberg B,et al.Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms.Exp Cell Res.2005,305:33-41.
[31]Liu J,Lu XF,Wan L et al.Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbredline.Transplant Proc.2004,36:3272-3275.
[32]Glennie S,Soeiro I,Dyson PJ,et al.Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.Blood.2005,105:2821-2827.
[33]Blazar BR,Taylor PA.Regulatory T cells.Biol Blood Marrow Transplant.2005,11:46-49.
[34]Taylor PA,Lees CJ,Blazar BR.The infusion of ex vivo activated and expanded CD4~+CD25~+ immune regulatory cells inhibits graft-versus-host disease lethality.Blood.2002,99:3493-3499.
[35]Aggarwal S,Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood.2005,105:1815-1822.
[36]Maccario R,Podesta M,Moretta A et al.Interaction of human mesenchymal stem cells with cells involved in alloantigenspecific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype.Haematologica.2005,90:516-525.
[37]Groh ME,Maitra B,Szekely E,et al.Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells.Exp Hematol.2005,33:928-934.
[38]Feinberg K,Silvestri G.T(S) cells and immune tolerance induction:a regulatory renaissance?Nat Immunol.2002,3:215-217.
[39]Le Blanc K,Rasmusson I,Sundberg B et al.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.Lancet.2004,363:1439-1441.
[40]Meisel R,Zibert A,Laryea M,et al.Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.Blood.2004,103:4619-4621.
[41]Arikawa T,Omura K,Morita I.Regulation of bone morphogenetic protein-2expression by endogenous prostaglandin E2 in human mesenchymal stem cells.J Cell Physiol.2004,200:400-406.
[42]Corcione A,Benvenuto F,Ferretti E et al.Human mesenchymal stem cells modulate B-cell functions.Blood.2006,107:367-372.
[43]Friedenstein A,Kuralesova AI.Osteogenic precursor cells of bone marrow in radiation chimeras.Transplantation.1971,12:99-108.
[44]Jiang XX,Zhang Y,Liu B et al.Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.Blood.2005,105:4120-4126.
[45]Svensson M,Maroof A,Ato M,et al.Stromal cells direct local differentiation of regulatory dendritic cells.Immunity.2004,21:805-816.
[46]Spaggiari GM,Capobianco A,Becchetti S,et al.Mesenchymal stem cell-natural killer cell interactions:evidence that activated NK cells are capable of killing MSCSS whereas MSCSS can inhibit IL-2-induced NK-cell proliferation.Blood.2006,107:1484-1490.
[47]Rasmusson I,Le Blanc K,Sundberg B,et al.Mesenchymal stem cells stimulate antibody secretion in human B cells.Scand J Immunol.2007,65:336-343.
[48]邓为民,韩钦,葛薇等.骨髓源间充质干细胞在异基因小鼠免疫器官内的分布及其免疫功能调节作用.中国免疫学杂志.2004,20:40-45.
[49]Wang JW,Liu YB,Xu B,et al.The study on immunomodulation of donor mesenchymal stem cells on discordant liver xenotransplantation.Zhonghua Waike Zazhi.2005,43:928-934.
[50]Eliopoulos N,Stagg J,Lejeune L,et al.Allogeneic marrow stromal cells are immune rejected by MHC class Ⅰ-and class Ⅱ-mismatched recipient mice.Blood.2005,106:4057-4065.
[51]Fouillard L,Bensidhoum M,Bories D,et al.Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma.Leukemia.2003,17:474-476.
[52]Le Blanc K,Gotherstrom C,Ringden O,et al.Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta.Transplantation.2005,79:1607-1614.
[53]Koc ON,Peters C,Aubourg P,et al.Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases.Exp Hematol.1999,27:1675-1681.
[54]Krivit W,Shapiro EG,Lockman LA,et al.Bone marrow transplantation:treatment for globoid cell leukodystrophy,metachromatic leukodystrophy,adrenoleukodystrophy and Hurler syndrome.In:Moser HW,Vinken PJ,Bruyn GW,eds.Handbook of Clinical Neurology.Amsterdam:Elsevier Science.1996,87-106.
[55]Koc ON,Day J,Nieder M,et al.Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy(MLD) and Hurler syndrome(MPS-IH).Bone Marrow Transplant.2002,30:215-222.
[56]Horwitz EM,Prockop DJ,Gordon PL,et al.Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta.Blood.2001,97:1227-1231.
[57]Horwitz EM,Gordon PL,Koo WK,et al.Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta:Implications for cell therapy of bone.Proc Natl Acad Sci U S A.2002,99:8932-8937.
[58]Lee ST,Jang JH,Cheong JW,et al.Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype.Br J Haematol.2002,118:1128-1131.
[59]Le Blanc K,Gustafsson B,Remberger,M et al.Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.Leukemia.2007,21:1733-1738.
[60]Lazarus HM,Koc ON,Devine SM,et al.Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant.2005,11:389-398.
[61]Cahill RA,Jones OY,Klemperer,M et al.Replacement of recipient stromal/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells.Biol Blood Marrow Transplant.2004,10:709-717.
[62]Ringd(?)n O,Uzunel M,Rasmusson I,et al.Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.Transplantation.2006,81:1390-1397.
[63]Le Blanc K,Frassoni F,Uzunel M,et al.Mesenchymal stem cells for treatment of severe graft-versus-host disease.Blood.2006,108:753.
[64]Ringden O,Uzunel M,Sundberg B,et al.Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis,pneumomediastinum and perforated colon.Leukaemia.2007,21:2271-2276.
[65]Wu GD,Nolta JA,Jin YS,et al.Migration of mesenchymal stem cells to heart allografts during chronic rejection.Transplantation.2003,75:679-685.
[66]Sundin M,Orvell C,Rasmusson I,et al.Mesenchymal stem cells are susceptible to human herpesviruses,but viral DNA cannot be detected in the healthy seropositive individual.Bone Marrow Transplant.2006,37: 1051-1059.
[67]Horowitz MM,Gale RP,Sondel PM et al.Graft-versus-leukemia reactions after bone marrow transplantation.Blood.1990,75:555-562.
[68]Ringden O,Hermans J,Labopin M,et al.The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade Ⅰ acute graft-versus-host disease.Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT).Leuk Lymphoma.1996,24:71-79.
[69]Hematti P.Role of mesenchymal stromal cells in solid organ transplantation.Transplant Rev.2008,22:262-273.